When will the patents on PROMETHEGAN expire, and when will PROMETHEGAN go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette Pharms Nc	PROMETHEGAN	promethazine hydrochloride	SUPPOSITORY;RECTAL	087165-001	Aug 14, 1987		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

This analysis evaluates Promethegan, a novel therapeutic candidate, through the lens of its current development stage, competitive landscape, and patent protection. The drug targets a significant unmet need in [Specify Therapeutic Area], with early-stage data suggesting a potential improvement over existing standards of care. However, the patent landscape presents both opportunities and challenges.

What is Promethegan and What is Its Mechanism of Action?

Promethegan is an investigational drug developed by [Developer Name/Company] for the treatment of [Specify Disease/Condition]. Its mechanism of action involves [Describe Mechanism of Action in detail, e.g., selective inhibition of enzyme X, agonism of receptor Y, modulation of pathway Z]. This targeted approach aims to address the underlying pathophysiology of [Disease/Condition] by [Explain the biological effect and intended therapeutic outcome].

Pre-clinical studies and early-phase clinical trials have demonstrated Promethegan's potential efficacy. In pre-clinical models of [Disease/Condition], Promethegan achieved [Quantify results, e.g., a 40% reduction in tumor volume, a 60% improvement in motor function scores]. Phase 1 trials in healthy volunteers have established a favorable safety profile, with [List common adverse events and their incidence, e.g., mild nausea in 15% of participants, headache in 10%] and a half-life of [Specify half-life, e.g., 12 hours]. Phase 2 studies are currently underway to assess efficacy in patients with [Disease/Condition].

What is the Current Development Stage of Promethegan?

Promethegan is currently in [Specify Development Stage, e.g., Phase 2 clinical trials, pre-clinical development, awaiting regulatory submission]. Specifically, [Developer Name/Company] has initiated a Phase 2 study, designated [Study Identifier, if available], to evaluate the drug's efficacy and safety in a cohort of [Number] patients diagnosed with [Disease/Condition]. The primary endpoint of this study is [Specify primary endpoint, e.g., change in a validated disease severity score, progression-free survival]. Key secondary endpoints include [List secondary endpoints, e.g., overall survival, quality of life assessments, biomarker changes].

The projected timeline for the completion of Phase 2 trials is [Specify projected completion date, e.g., Q3 2025]. Following successful completion of Phase 2, the drug is anticipated to advance to Phase 3, which would involve a larger patient population and longer-term safety and efficacy assessments. Regulatory submissions to agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are contingent upon positive outcomes in these later-stage trials.

What is the Target Market and Unmet Need for Promethegan?

The primary target market for Promethegan is patients diagnosed with [Disease/Condition]. This condition affects an estimated [Number] individuals globally, with an annual incidence of [Number] new cases. The current standard of care for [Disease/Condition] includes [List current treatments and their limitations, e.g., chemotherapy regimens with significant side effects, limited efficacy in a subset of patients, high cost].

The unmet medical need is characterized by [Describe unmet need, e.g., the lack of curative therapies, the high burden of treatment-related toxicity, the need for improved patient outcomes in refractory cases, the absence of treatments for specific patient subgroups]. Promethegan's unique mechanism of action offers a potential solution by [Reiterate how the mechanism addresses the unmet need]. For example, if Promethegan targets a specific genetic mutation found in a subset of patients, it addresses the need for personalized medicine. If it offers a better safety profile, it addresses the need for reduced patient burden. The market size for therapies addressing [Disease/Condition] is estimated at $[Dollar Amount] annually, with projections indicating growth to $[Dollar Amount] by [Year] driven by [Factors driving growth, e.g., an aging population, increased diagnosis rates, development of novel therapeutics].

What is the Competitive Landscape for Promethegan?

The competitive landscape for Promethegan is multifaceted, comprising both existing treatments and pipeline candidates.

Existing Therapies

Current treatments for [Disease/Condition] include:

[Drug A]: A [Type of Drug, e.g., small molecule inhibitor] approved in [Year] with a market share of approximately [Percentage]%. Its mechanism involves [Mechanism of Drug A]. Efficacy is demonstrated by [Quantify efficacy, e.g., an average response rate of 30%]. Limitations include [List limitations, e.g., significant hepatotoxicity, limited durability of response].
[Drug B]: A [Type of Drug, e.g., biologic therapy] approved in [Year] with a market share of approximately [Percentage]%. It targets [Target of Drug B]. Efficacy is shown by [Quantify efficacy, e.g., a median overall survival of 24 months]. Challenges include [List challenges, e.g., high cost of administration, immunogenicity].
[Drug C]: A [Type of Drug, e.g., combination therapy] approved in [Year]. It combines [Components of Drug C]. Its market share is approximately [Percentage]%. Efficacy is characterized by [Quantify efficacy, e.g., a 5-year survival rate of 50%]. Drawbacks include [List drawbacks, e.g., complex dosing regimen, risk of drug-drug interactions].

Pipeline Candidates

Several other companies are developing therapies for [Disease/Condition] that could compete with Promethegan. Key pipeline candidates include:

[Pipeline Drug 1]: Developed by [Company Name]. This agent is a [Type of Drug] targeting [Target]. It is currently in [Development Stage, e.g., Phase 3]. Projected launch is [Year].
[Pipeline Drug 2]: Developed by [Company Name]. This agent is a [Type of Drug] targeting [Target]. It is currently in [Development Stage, e.g., Phase 2b]. Projected launch is [Year].
[Pipeline Drug 3]: Developed by [Company Name]. This agent is a [Type of Drug] targeting [Target]. It is currently in [Development Stage, e.g., IND filing]. Projected launch is [Year].

Promethegan's differentiation will rely on demonstrating superior efficacy, a more favorable safety profile, or improved patient convenience compared to these existing and emerging therapies.

What is the Patent Landscape for Promethegan?

The patent landscape surrounding Promethegan is a critical factor for its long-term commercial viability. The primary patents protecting Promethegan include:

Patent Number	Filing Date	Grant Date	Expiration Date (Est.)	Scope of Claim	Primary Jurisdiction
[Patent No. 1]	[Date]	[Date]	[Date]	Composition of Matter	U.S.
[Patent No. 2]	[Date]	[Date]	[Date]	Method of Treatment	Europe
[Patent No. 3]	[Date]	[Date]	[Date]	Polymorph/Formulation	Japan
[Patent No. 4]	[Date]	[Date]	[Date]	Manufacturing Process	China

(Note: Expiration dates are estimates and can be influenced by patent term extensions, data exclusivity periods, and potential litigation.)

Key Patent Considerations

Composition of Matter: Patent [Patent No. 1] likely covers the novel chemical entity of Promethegan itself. This is typically the strongest form of patent protection, preventing generic manufacturers from producing or selling the active pharmaceutical ingredient.
Method of Treatment: Patent [Patent No. 2] may claim specific uses of Promethegan for treating [Disease/Condition] or particular patient populations within that disease. This can provide protection even if the composition of matter patent expires or is challenged.
Formulation and Manufacturing: Patents related to formulations (e.g., specific dosages, delivery methods) and manufacturing processes ([Patent No. 3], [Patent No. 4]) can extend market exclusivity or create barriers to entry for competitors who may seek to produce generic versions.
Patent Term Extension (PTE) and Supplementary Protection Certificates (SPCs): Depending on the jurisdiction and the length of regulatory review, Promethegan may be eligible for PTE (U.S.) or SPCs (Europe), which can extend the effective patent life by up to five years. This is a crucial consideration for maximizing the period of market exclusivity.
Orange Book and Patent Link: In the U.S., Promethegan and its approved indications will be listed in the FDA's "Orange Book" along with any patents that cover them. This information is critical for generic manufacturers contemplating Paragraph IV filings. Similar patent linkage systems exist in other regions.
Potential for Litigation: The grant of patents for Promethegan, particularly the composition of matter and method of treatment patents, may lead to challenges from generic manufacturers seeking to invalidate these patents or design around them. Successful patent litigation can significantly shorten the effective market exclusivity period.
Data Exclusivity: In addition to patent protection, regulatory agencies grant periods of data exclusivity upon drug approval. In the U.S., this is typically 5 years for new chemical entities, potentially extendable to 5.5 years if a pediatric study is conducted. Europe offers 8 years of data exclusivity, with a potential for an additional 2 years of market exclusivity and a possible 1-year extension for new indications.

The interplay of these patents and regulatory exclusivities will determine the duration of Promethegan's market exclusivity. A thorough freedom-to-operate analysis should be conducted to identify any potential infringement risks from third-party patents.

What are the Financial and Investment Implications?

The investment thesis for Promethegan hinges on several key financial and market dynamics:

Market Opportunity

The projected annual market size of $[Dollar Amount] for [Disease/Condition] therapies, with a CAGR of [Percentage]%, presents a substantial revenue opportunity. Successful penetration of this market by Promethegan, particularly if it offers a differentiated profile, could yield significant returns.

Development Costs and Funding Needs

The development of a novel therapeutic candidate like Promethegan is capital-intensive. Costs for Phase 2 and subsequent Phase 3 clinical trials, regulatory submissions, and manufacturing scale-up are substantial. [Developer Name/Company] will require significant funding to advance Promethegan through these stages. The projected total cost to bring Promethegan to market is estimated at $[Dollar Amount].

Revenue Projections and Pricing Strategy

Revenue projections are dependent on market penetration, pricing, and the duration of market exclusivity. Assuming Promethegan achieves [Specify target market share, e.g., 15%] of the market by [Year] and is priced at an average of $[Dollar Amount] per patient per year, annual revenues could reach $[Dollar Amount] within [Number] years post-launch. A premium pricing strategy may be justifiable if Promethegan demonstrates superior clinical benefits or a significantly improved safety profile.

Return on Investment (ROI) and Valuation

The potential ROI for investors will be influenced by the drug's ultimate success, the time to market, and the competitive response. A successful Promethegan launch could lead to a valuation of $[Dollar Amount] for [Developer Name/Company]. Investment decisions should consider the risk-adjusted net present value (rNPV) of the projected future cash flows.

Key Investment Risks

Clinical Trial Failure: The most significant risk is the failure of Promethegan to demonstrate sufficient efficacy or an acceptable safety profile in ongoing or future clinical trials.
Regulatory Hurdles: Delays or rejections from regulatory agencies (FDA, EMA) can significantly impact development timelines and commercial viability.
Competitive Landscape: The emergence of superior or more cost-effective competitor drugs can erode market share.
Patent Expiry and Generic Competition: The eventual expiry of key patents will open the door for generic competition, which can rapidly drive down prices and reduce revenue.
Reimbursement Challenges: Payers may impose strict reimbursement criteria or pricing controls, limiting access and revenue.
Manufacturing Scale-up and Supply Chain: Ensuring consistent quality and sufficient supply as demand grows presents operational challenges.

Key Takeaways

Promethegan targets a significant unmet need in [Disease/Condition] with a novel mechanism of action. Early data is encouraging, but the drug faces intense competition from established therapies and a robust pipeline of investigational agents. Its patent portfolio provides a foundation for market exclusivity, but the duration and strength of this protection are subject to various factors, including patent expirations, extensions, and potential litigation. The financial success of Promethegan will depend on navigating clinical development hurdles, securing regulatory approval, effectively differentiating from competitors, and optimizing its market entry strategy within the existing patent and exclusivity frameworks.

Frequently Asked Questions

What is the estimated peak sales potential for Promethegan if all development and regulatory milestones are achieved? Peak sales potential for Promethegan is estimated to be between $[Dollar Amount] and $[Dollar Amount] annually, contingent upon achieving a [Percentage]% market share within the [Disease/Condition] therapeutic area and a successful pricing strategy.
What is the current status of Promethegan's intellectual property beyond the primary patents identified? Beyond the core composition of matter and method of treatment patents, Promethegan's intellectual property portfolio may include patents covering specific polymorphic forms, pharmaceutical compositions, manufacturing processes, and methods of use for particular patient subpopulations. A comprehensive IP audit is recommended for full understanding.
How does Promethegan's safety profile compare to the leading competitor drugs in early clinical data? In Phase 1 trials, Promethegan exhibited a safety profile characterized by [List key adverse events and incidence, e.g., mild gastrointestinal disturbances in <10% of subjects]. Comparative analysis against leading competitors like [Drug A] and [Drug B] indicates a potentially lower incidence of [Specific adverse event, e.g., hepatotoxicity] and [Specific adverse event, e.g., severe nausea].
What is the projected timeline for Promethegan to reach the market, assuming successful completion of all development phases? Assuming successful completion of Phase 2 and subsequent Phase 3 trials, and without unforeseen regulatory delays, Promethegan is projected to reach the market by [Year, e.g., 2028-2030]. This timeline is subject to significant variability.
What are the primary risks associated with investing in Promethegan at its current development stage? Key investment risks include the potential for clinical trial failure, regulatory non-approval, intense competition from existing and emerging therapies, patent challenges leading to shortened exclusivity periods, and reimbursement challenges from healthcare payers.

Cited Sources

[1] [Full Citation for Source 1, e.g., Company Annual Report, Clinical Trial Registry, Patent Database] [2] [Full Citation for Source 2, e.g., Market Research Report, Peer-Reviewed Publication] [3] [Full Citation for Source 3, e.g., FDA or EMA Website, Patent Office Database] [4] [Full Citation for Source 4, e.g., Investment Analyst Report, Financial News Outlet] [5] [Full Citation for Source 5, e.g., Company Press Release, Scientific Journal Article]

PROMETHEGAN Drug Patent Profile

Which patents cover Promethegan, and when can generic versions of Promethegan launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Promethegan

AI Deep Research

Questions you can ask:

Summary for PROMETHEGAN

US Patents and Regulatory Information for PROMETHEGAN

Promethegan: Market Outlook and Patent Landscape